ClinicalTrials.gg
TerminatedNCT03383146Updated Nov 23, 2021Results posted

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

A Phase 3 interventional study of Placebo and Relamorelin in Gastroparesis and Diabetes Mellitus, sponsored by Allergan. Terminated at 349 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-23.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
The Relamorelin program is being terminated solely based on a business decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.

Enrollment
4th of 136
450 · median 36
Started
2018
with 11 others
Phase 3
12 of 184
none open now
Registered
89th of 184
by date
Lead sponsor
6 of 184
Allergan

Among the 184 studies in Gastroparesis with a site in United States, this one is the 4th largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2018, is one of 12 in phase 3, and was the 89th registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Gastroparesis with a site in United States, or all of them as a file.
02

Study summary

A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.

03

Conditions studied

  • Gastroparesis
  • Diabetes Mellitus

Keywords

  • diabetic gastroparesis
  • vomiting
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Two different groups of participants may enter into the study:

  1. Rollover Participants

    Participants who were not randomization-eligible at the end of the Run-in Period of lead-in studies RLM-MD-01 (NCT03285308) or RLM-MD-02 (NCT03426345) are eligible to be randomized in the study if all of the following criteria apply:

    •In the lead-in studies, participants must have met all screening visit and Run-in Period criteria for randomization into the Treatment Period (including compliance with dosing, entry of diary data into the Diabetic Gastroparesis Symptom Severity Diary (DGSSD)) except that:

    • They had zero vomiting episodes and an average daily Diabetic Gastroparesis Symptom Severity Score (DGSSS) of ≥12 at the end of the lead-in study Run-in Period, as reported using the electronic hand-held device; OR
    • They had vomiting episodes and an average daily DGSSS of ≥12 but \<16 at the end of the lead-in study Run-in Period, as reported using the electronic hand-held device
  2. De Novo Participants

    • Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM) of at least 5 years' duration, with controlled and stable blood glucose levels and (HBA1c) ≤11%
    • DG defined as at least a 3-month history prior to Screening of symptoms (one of which must be nausea) on an ongoing basis that are suggestive of gastroparesis (GP) (e.g., nausea, abdominal pain, postprandial fullness, bloating, vomiting, and early satiety)
    • Compliance with the entry of data into the hand-held electronic device during the Run-in Period
    • Compliance with administration of subcutaneous (SC) twice daily injections during the Run-in Period
    • The average of the daily DGSSS from the 2-week, Run-in Period must be ≥12

Exclusion criteria

Exclusion Criteria:

  1. Both Rollover and De Novo Participants

    •Participants with a known allergy or to the study treatments and their (i.e., mannitol or phenol)

  2. Rollover Participants

    •Participants will be excluded from this study if any of the lead-in study exclusion criteria apply at the Screening Visit and at the end of the Run-in Period for randomization into the Treatment Period of studies RLM-MD-01 and RLM-MD-02, except as specified in the inclusion criteria

  3. De Novo Participants

    • History of anorexia nervosa, binge-eating, bulimia, or other eating disorder within 5 years of the Screening Visit
    • History of intestinal malabsorption or pancreatic exocrine insufficiency
    • History of belching disorders, other nausea and vomiting disorders
    • Gastric or duodenal ulcer within 3 months of Screening
    • History of in the 3 years prior to Screening, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
    • Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube for feeding or decompression
    • Use of metoclopramide, domperidone, prucalopride, macrolide antibiotics (e.g., erythromycin, clarithromycin, azithromycin), or other drugs considered to be GI promotility agents for at least 10 days prior to the start of the Run-in Period
    • Currently taking opiates, or expecting to use opiates during the course of the clinical study
    • Treatment with glucagon-like peptide-1 (GLP-1) agonist for at least 6 weeks prior to the start of the Run-in Period
    • History of pyloric injection of botulinum toxin within 6 months of screening
    • History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, or bariatric procedure (a history of diagnostic endoscopy is not exclusionary)
    • Randomization in any previous study in which relamorelin was a treatment
    • Allergic to, or intolerant of egg, wheat, milk, or algae, as these are components of the gastric emptying breath test (GEBT) study meal
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
450 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.

    Drug: Placebo

  • Experimental
    Relamorelin 10 μg

    Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.

    Drug: Relamorelin

Interventions

  • DrugPlacebo

    Placebo injected subcutaneously twice daily.

  • Relamorelin 10 μg injected subcutaneously twice daily.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)

    Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.

    Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 12 of this study

  2. Change From Baseline to Week 52 in the Weekly Average DGSSS

    Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). The average weekly scores at Week 52 were the average of the DGSSS scores from Week 49 to Week 52. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.

    Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 52 of this study

  3. Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.

    Time frame: First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 56 weeks)

  4. Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results

    Clinical Laboratory tests included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 participant had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

    Time frame: Up to 52 weeks

  5. Number of Participants With Clinically Meaningful Trends for Vital Signs

    Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the abnormal results were clinically significant.

    Time frame: Up to 52 weeks

  6. Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results

    A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.

    Time frame: Up to 52 weeks

  7. Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HbA1c)

    Time frame: Up to 52 weeks

  8. Number of Participants With Anti-relamorelin Antibody Testing Results by Visit

    A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay. The number of participants in each of the following categories are reported: Negative Screening Test, Positive Screening Test, Negative Confirmatory Test, and Positive Confirmatory Test at each time point.

    Time frame: Baseline (Day 1), Day 84, Day 364, and End of Treatment (Up to Day 364)

07

Results

Posted Nov 23, 2021

Participant flow

Participant flow — Overall Study
MilestonePlaceboRelamorelin 10 μg
Started148302
Safety population145299
Run-in period91207
Completed63118
Not completed85184
Withdrew: Screen failure10
Withdrew: Adverse event618
Withdrew: Lack of efficacy03
Withdrew: Withdrawal by subject2036
Withdrew: Lost to follow-up515
Withdrew: Death02
Withdrew: Physician decision01
Withdrew: Protocol deviation18
Withdrew: Study terminated by the sponsor4895
Withdrew: Reason not specified46

Outcome measures

PrimaryChange From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)

Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.

Time frame:
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 12 of this study
Reported as:
Mean · score on a scale
Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)
score on a scalePlaceboRelamorelin 10 μg
Baseline20.3 ± 6.7019.7 ± 6.39
Change from Baseline to Week 12-7.1 ± 8.82-6.5 ± 7.80
PrimaryChange From Baseline to Week 52 in the Weekly Average DGSSS

Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). The average weekly scores at Week 52 were the average of the DGSSS scores from Week 49 to Week 52. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.

Time frame:
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 52 of this study
Reported as:
Mean · score on a scale
Change From Baseline to Week 52 in the Weekly Average DGSSS
score on a scalePlaceboRelamorelin 10 μg
Baseline20.3 ± 6.7019.7 ± 6.39
Change from Baseline to Week 52-10.7 ± 8.93-8.6 ± 8.92
PrimaryNumber of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.

Time frame:
First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)
ParticipantsPlaceboRelamorelin 10 μg
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)105221
PrimaryNumber of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results

Clinical Laboratory tests included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 participant had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results
ParticipantsPlaceboRelamorelin 10 μg
Hematocrit (RATIO): >1.1×Upper Limit of Normal Value (ULN)01
Hematocrit (RATIO): <0.9×Lower Limit of Normal Value (LLN)514
Hemoglobin (gram(g)/L): <0.9×LLN1020
Lymphocytes Absolute Cell Count (10^9/(Liter(L)): >1.5×ULN15
Lymphocytes Absolute Cell Count (10^9/L): <0.8×LLN29
Mean Corpuscular Volume [femtoliter(fL)]: >1.1×ULN22
Neutrophils Absolute Cell Count (10^9/L): >1.5×ULN20
Neutrophils Absolute Cell Count (10^9/L): <0.8×LLN73
Red Blood Cell Count (10^12/L):<0.9×LLN210
White Blood Cell Count (10^9/L): <0.7×LLN20
Alanine Aminotransferase (Serum Glutamate-Pyruvate transaminase (SGPT)) (Unit (U)/L): ≥3.0×ULN06
Albumin (gram (g)/L): <0.9×LLN01
Alkaline Phosphatase (U/L): ≥3.0×ULN01
Aspartate Aminotransferase (Serum Glutamic-Oxaloacetic Transaminase (SGOT)) (U/L): ≥3.0×ULN23
Bicarbonate (HCO3) (millimole (mmol)/L): >1.1×ULN32
Bicarbonate (HCO3) (millimole (mmol)/L): >1.1×LLN32
Bicarbonate (HCO3) (millimole (mmol)/L): <0.9×LLN66
Bilirubin, Total (micromole (umol)/L): >1.5×ULN01
Blood Urea Nitrogen (mmol/L): >1.2×ULN1427
Calcium (mmol/L): >1.1×ULN01
Chloride (mmol/L): <0.9×LLN11
Cholesterol, Total, Fasting (mmol/L): >1.6×ULN25
Creatinine (umol/L): >1.3×ULN1520
Glucose-Chemistry, Fasting (mmol/L): >2.5×ULN2252
Glucose-Chemistry, Fasting (mmol/L): <0.9×LLN414
Glycohemoglobin A1C (%): Increase of ≥0.5%95247
Glycohemoglobin A1C (%): Increase of ≥1%94246
Phosphorus (mmol/L): >1.1×ULN135
Phosphorus (mmol/L): <0.9×LLN14
Potassium (mmol/L): <0.9×LLN10
Protein, Total (g)/L): >1.1×ULN10
Triglycerides, Fasting (mmol/L): ≥3.0×ULN89
Uric Acid (Urate) (umol/L): >1.1×ULN1737
Uric Acid (Urate) (umol/L): <0.9×LLN19
PrimaryNumber of Participants With Clinically Meaningful Trends for Vital Signs

Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the abnormal results were clinically significant.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Trends for Vital Signs
ParticipantsPlaceboRelamorelin 10 μg
Number of Participants With Clinically Meaningful Trends for Vital Signs00
PrimaryNumber of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results

A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results
ParticipantsPlaceboRelamorelin 10 μg
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results22
PrimaryNumber of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HbA1c)
Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HbA1c)
ParticipantsPlaceboRelamorelin 10 μg
Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HbA1c)94246
PrimaryNumber of Participants With Anti-relamorelin Antibody Testing Results by Visit

A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay. The number of participants in each of the following categories are reported: Negative Screening Test, Positive Screening Test, Negative Confirmatory Test, and Positive Confirmatory Test at each time point.

Time frame:
Baseline (Day 1), Day 84, Day 364, and End of Treatment (Up to Day 364)
Reported as:
Count of participants · Participants
Number of Participants With Anti-relamorelin Antibody Testing Results by Visit
ParticipantsRelamorelin 10 μg
Screening Test (Baseline) — Negative127
Screening Test (Baseline) — Positive39
Confirmatory Test (Baseline) — Negative5
Confirmatory Test (Baseline) — Positive0
Screening Test (Day 84) — Negative73
Screening Test (Day 84) — Positive23
Confirmatory Test (Day 84) — Negative6
Confirmatory Test (Day 84) — Positive1
Screening Test (Day 364) — Negative10
Screening Test (Day 364) — Positive4
Confirmatory Test (Day 364) — Negative—
Confirmatory Test (Day 364) — Positive—
Screening Test (End of Treatment) — Negative20
Screening Test (End of Treatment) — Positive6
Confirmatory Test (End of Treatment) — Negative1
Confirmatory Test (End of Treatment) — Positive0
Screening Test (Unscheduled) — Negative2
Screening Test (Unscheduled) — Positive1
Confirmatory Test (Unscheduled) — Negative1
Confirmatory Test (Unscheduled) — Positive0

Adverse events

Collected over First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 56 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/148 (0%)21/145 (14.5%)37/145 (25.5%)
Relamorelin 10 μg2/302 (0.7%)43/299 (14.4%)82/299 (27.4%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventPlaceboRelamorelin 10 μg
PneumoniaInfections and infestations2/1451/299
FallInjury, poisoning and procedural complications0/1453/299
AsthmaRespiratory, thoracic and mediastinal disorders1/1453/299
Acute left ventricular failureCardiac disorders1/1451/299
Cardiac failureCardiac disorders1/1450/299
Sinus tachycardiaCardiac disorders1/1450/299
PancreatitisGastrointestinal disorders1/1451/299
Abdominal pain upperGastrointestinal disorders1/1450/299
ConstipationGastrointestinal disorders1/1450/299
Diabetic gastroparesisGastrointestinal disorders1/1450/299
Most frequent other events
Most frequent other events
EventPlaceboRelamorelin 10 μg
DiarrhoeaGastrointestinal disorders14/14521/299
Urinary tract infectionInfections and infestations9/14528/299
ArthralgiaMusculoskeletal and connective tissue disorders11/14518/299
HyperglycaemiaMetabolism and nutrition disorders8/14515/299
HeadacheNervous system disorders7/14515/299

Baseline characteristics

Intent-to-treat (ITT) Population included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboRelamorelin 10 μgTotal
Mean57.0 ± 12.3757.9 ± 11.5757.6 ± 11.84
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRelamorelin 10 μgTotal
Female102224326
Male4678124
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRelamorelin 10 μgTotal
Hispanic or Latino5082132
Not Hispanic or Latino98220318
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRelamorelin 10 μgTotal
American Indian or Alaska Native71118
Asian099
Native Hawaiian or Other Pacific Islander101
Black or African American275380
White109218327
More than one race41115
Unknown or Not Reported000
08

Study locations

349 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • North Alabama Research Center, LLC
    Athens, Alabama 35611, United States
  • Simon Williamson Clinic
    Birmingham, Alabama 35211, United States
  • Digestive Health Specialist of the South East
    Dothan, Alabama 36305, United States
  • G & L Research, LLC
    Foley, Alabama 36535, United States
  • Avant Research Associates
    Huntsville, Alabama 35801, United States
  • Alabama Medical Group, PC
    Mobile, Alabama 36608, United States
  • Phoenix Clinical LLC.
    Phoenix, Arizona 85014, United States
  • Del Sol Research Management, LLC
    Tucson, Arizona 85710, United States
  • Del Sol Research Management, LLC
    Tucson, Arizona 85712, United States
  • Synexus Clinical Research US, Inc.
    Tucson, Arizona 85741, United States
  • Preferred Research Partners, Inc.
    Little Rock, Arkansas 72211, United States
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72212, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • Unity Health - Searcy Medical Center
    Searcy, Arkansas 72143, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • GW Research Inc
    Chula Vista, California 91910, United States
  • Kindred Medical Institute for Clinical Trials, LLC
    Corona, California 92879, United States
  • Aurora Care Clinic, LLC
    Costa Mesa, California 92627, United States
  • TriWest Research Associates
    El Cajon, California 92020, United States
  • Diagnamics Inc.
    Encinitas, California 92024, United States
  • VVCRD Research
    Garden Grove, California 92845, United States
  • University of California San Diego
    La Jolla, California 92037, United States
  • Om Research LLC
    Lancaster, California 93534, United States
  • Torrance Clinical Research Institute, Inc.
    Lomita, California 90717, United States
  • Angel City Research Inc.
    Los Angeles, California 90057, United States
  • Stanford Hospital
    Palo Alto, California 94304, United States
  • Optimal Research California
    San Diego, California 92108, United States
  • Medical Associates Research Group, Inc
    San Diego, California 92123, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Upland Clinical Research
    Upland, California 91786, United States
  • Synexus Clinical Research US, Inc.
    Vista, California 92083, United States
  • New Hope Research Development
    Whittier, California 90603, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • Synexus
    Colorado Springs, Colorado 80909, United States
  • Gastroenterology Associates of Fairfield County, P.C.
    Bridgeport, Connecticut 06606, United States
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Innovative Research of West FL, Inc.
    Clearwater, Florida 33756, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • ALL Medical Research, LLC
    Cooper City, Florida 33024, United States
  • Top Medical Research
    Cutler Bay, Florida 33189, United States
  • Palmetto Research, LLC
    Hialeah, Florida 33016, United States
  • Vida Clinical Trials
    Homestead, Florida 33030, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Savin Medical Group LLC
    Miami Lakes, Florida 33014, United States
  • APF Research LLC
    Miami, Florida 33134, United States
  • AMPM Research Clinic
    Miami, Florida 33169, United States
  • Advanced Medical Research Institute
    Miami, Florida 33174, United States
  • Florida Research Center, Inc.
    Miami, Florida 33174, United States
  • American Research Institute, Inc
    Miami, Florida 33175, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Sensible Healthcare
    Ocoee, Florida 34761, United States
  • Synexus
    Pinellas Park, Florida 33781, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30318, United States
  • River Birch Research Alliance, LLC
    Blue Ridge, Georgia 30513, United States
  • Gwinnett Research Institute, LLC
    Buford, Georgia 30519, United States
  • Summit Clinical Research, LLC.
    Carnesville, Georgia 30521, United States
  • iResearch Atlanta LLC
    Decatur, Georgia 30030, United States
  • Infinite Clinical Trials
    Riverdale, Georgia 30274, United States
  • Clinical Research Consultants of Atlanta
    Suwanee, Georgia 30024, United States
  • Rocky Mountain Diabetes and Osteoporosis Center, PA
    Idaho Falls, Idaho 83404-7596, United States
  • North Shore University Health System
    Evanston, Illinois 60201, United States
  • Southwest Gastroenterology
    Oak Lawn, Illinois 60453, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • Synexus Clinical Research US, Inc.
    Evansville, Indiana 47714, United States
  • American Research, LLC
    Jeffersonville, Indiana 47130, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Health Science Research Center
    Pratt, Kansas 67124, United States
  • WestGlen Gastrointestinal Consultants
    Shawnee Mission, Kansas 66217, United States
  • Cotton-O'Neil Clinical Research Center - Digestive Health
    Topeka, Kansas 66606, United States
  • Kansas Medical Clinic
    Topeka, Kansas 66606, United States
  • Professional Research Network of Kansas, LLC
    Wichita, Kansas 67205, United States
  • Via Christi Clinic, PA
    Wichita, Kansas 67208, United States
  • St. Elizabeth Healthcare â€" Clinical Research Institute
    Erlanger, Kentucky 41018, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • WK Physicians Network
    Bossier City, Louisiana 71111, United States
  • Avant Research Associates LLC
    Crowley, Louisiana 70526, United States
  • Cronola LLC
    Houma, Louisiana 70360, United States
  • Clinical Trials of SWLA, LLC
    Lake Charles, Louisiana 70601, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Clinical Trials of America, Inc.
    West Monroe, Louisiana 71291, United States
  • Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Gastro Center of Maryland
    Columbia, Maryland 21045, United States
  • Frederick Gastroenterology Associates, PA an Elligo Health Research Site
    Frederick, Maryland 21701, United States
  • Woodholme Gastroenterology Associates, P.A.
    Glen Burnie, Maryland 21061, United States
  • Meritus Center for Clinical Research
    Hagerstown, Maryland 21742, United States
  • Meridian Clinical Research, LLC
    Rockville, Maryland 20854, United States
  • Clinical Research Institute of Michigan
    Chesterfield, Michigan 48047, United States
  • Vida Clinical Studies
    Dearborn, Michigan 48124, United States
  • Aa Mrc, Llc
    Flint, Michigan 48504, United States
  • National Clinical, LLC
    Hamtramck, Michigan 48212, United States
  • Gastroenterology Associates of Western Michigan, West Michigan Clinical Research Center
    Wyoming, Michigan 49519, United States
  • MNGI Digestive Health
    Coon Rapids, Minnesota 55446, United States
  • Synexus Clinical Research US, Inc.
    Richfield, Minnesota 55423, United States
  • Synexus Clinical Research US, Inc
    Saint Louis, Missouri 63141, United States
  • Montana Medical Research
    Missoula, Montana 59808, United States
  • Diabetes and Endocrine Associates, P.C.
    Omaha, Nebraska 68114, United States
  • Heartland Clinical Research, Inc
    Omaha, Nebraska 68134, United States
  • Excel Clinical Research
    Las Vegas, Nevada 89109, United States

Showing the first 100 of 349 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Nov 2020, 33 months.

Results were first posted in Nov 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2017
First posted
Dec 26, 2017
StartActual
Feb 1, 2018
Primary completionActual
Nov 5, 2020
CompletionActual
Nov 5, 2020
Results first posted
Nov 23, 2021
Last update
Nov 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03383146
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Dec 26, 2017
Start date
Feb 1, 2018
Primary completion
Nov 5, 2020
Completion
Nov 5, 2020
Results posted
Nov 23, 2021
Last update
Nov 23, 2021

Study contacts

Harvy Schneier
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relamorelin

Start the discussion